Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 10: | Line 10: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2018-11-22: Initial authorization | *2018-11-22: Initial authorization | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2018-08-21: new indications and a new dosage for the treatment of relapsed or refractory [[cutaneous T-cell lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' KW-0761 | *'''Code name:''' KW-0761 | ||
Revision as of 20:27, 8 June 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. [1][2][3]
Diseases for which it is used
History of changes in FDA indication
- 2018-08-08: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (Based on MAVORIC)
History of changes in EMA indication
- 2018-11-22: Initial authorization
History of changes in PMDA indication
- 2018-08-21: new indications and a new dosage for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo